Rafferty Asset Management’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.45M | Buy |
80,543
+36,286
| +82% | +$2.01M | 0.01% | 420 |
|
|
2025
Q1 | $2.14M | Sell |
44,257
-51,210
| -54% | -$2.48M | 0.01% | 559 |
|
|
2024
Q4 | $3.69M | Buy |
95,467
+5,591
| +6% | +$216K | 0.01% | 474 |
|
|
2024
Q3 | $4.04M | Buy |
89,876
+14,606
| +19% | +$657K | 0.01% | 463 |
|
|
2024
Q2 | $2.61M | Sell |
75,270
-163,938
| -69% | -$5.68M | 0.01% | 572 |
|
|
2024
Q1 | $6.92M | Buy |
239,208
+71,413
| +43% | +$2.07M | 0.03% | 379 |
|
|
2023
Q4 | $3.85M | Sell |
167,795
-182,486
| -52% | -$4.18M | 0.02% | 504 |
|
|
2023
Q3 | $5.84M | Buy |
350,281
+64,822
| +23% | +$1.08M | 0.03% | 358 |
|
|
2023
Q2 | $7.88M | Buy |
285,459
+132,072
| +86% | +$3.65M | 0.04% | 287 |
|
|
2023
Q1 | $3.53M | Sell |
153,387
-141,961
| -48% | -$3.27M | 0.02% | 472 |
|
|
2022
Q4 | $3.22M | Sell |
295,348
-51,587
| -15% | -$563K | 0.03% | 468 |
|
|
2022
Q3 | $2.93M | Buy |
346,935
+32,703
| +10% | +$276K | 0.03% | 422 |
|
|
2022
Q2 | $2.49M | Buy |
314,232
+106,138
| +51% | +$840K | 0.02% | 425 |
|
|
2022
Q1 | $4.93M | Buy |
208,094
+42,322
| +26% | +$1M | 0.03% | 398 |
|
|
2021
Q4 | $5.67M | Buy |
165,772
+96,642
| +140% | +$3.3M | 0.03% | 334 |
|
|
2021
Q3 | $1.23M | Buy |
69,130
+29,938
| +76% | +$531K | 0.01% | 759 |
|
|
2021
Q2 | $1.76M | Sell |
39,192
-36,784
| -48% | -$1.65M | 0.01% | 724 |
|
|
2021
Q1 | $1.97M | Buy |
75,976
+62,102
| +448% | +$1.61M | 0.01% | 633 |
|
|
2020
Q4 | $280K | Sell |
13,874
-14,126
| -50% | -$285K | ﹤0.01% | 844 |
|
|
2020
Q3 | $547K | Buy |
+28,000
| New | +$547K | 0.01% | 674 |
|